A formidable foe: carbapenem-resistant Acinetobacter baumannii and emerging nonantibiotic therapies.

A formidable foe: carbapenem-resistant Acinetobacter baumannii and emerging nonantibiotic therapies.

Watkins Richard R

Expert review of anti-infective therapy

2018

2018-08

*Carbapenem-resistant Acinetobacter baumannii; *decolonization; *hospital-acquired infections; *therapies; *vaccination; Acinetobacter baumannii/drug effects/*isolation & purification; Acinetobacter Infections – Microbiology; Acinetobacter Infections – Therapy; Acinetobacter Infections/microbiology/*therapy; Animals; Anti-Bacterial Agents/pharmacology; Antibiotics – Pharmacodynamics; Bacterial; Carbapenems – Pharmacodynamics; Carbapenems/pharmacology; Drug Resistance; Gram-Negative Aerobic Bacteria; Gram-Negative Aerobic Bacteria – Drug Effects; Humans; Microbial; Microbial Culture and Sensitivity Tests; Microbial Sensitivity Tests

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

591–593

8

16